Organicell Regenerative Medicine (OTCBB: BPSR), a clinical-stage biopharma company developing exosome-based regenerative therapies, has announced the release of a Case Report in the peer reviewed journal Frontiers in Medicine. This case study highlights the therapeutic potential of Organicell’s proprietary therapeutic, Zofin™, and its continued success as a drug candidate. [Read more…]
Celonic to Expand Cell and Gene Therapy CDMO Business with Facility in Switzerland
Celonic to Boost Its Cell and Gene Therapy (CGT) Production with a Facility in the Upcoming Life Science Parket Rheintal, located in Stein, Switzerland.
Celonic Group, a leading global CDMO specializing in the development and production of Advanced Therapy Medicinal Products (ATMP) and bio-therapeutics, announced a long-term lease agreement for a new production site and office space. The facility will span 91,500 square feet (8,500 sqm) in the WST-222 building at the Novartis-operated Life Science Park Rheintal. [Read more…]
Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie
Pharmaron Continues to Expand Its Capacity to Offer Commercial Manufacturing Services for CGT Products
February 28, 2021, BEIJING–Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) has entered into a definitive agreement to acquire Allergan Biologics Limited (“The ABL site”) in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions. [Read more…]
Regenerative Outcomes Launches Clinical Research Trial Management Services to Small Biotech Companies
Regenerative Outcomes, LLC, an emerging global provider of outsourced regulatory and drug development support services for the Regenerative Medicine industry, announced its agreement to provide comprehensive Clinical Trial Management services to small Biotech companies in support of their FDA clinical trials.
Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials
Well-established Mouse Model Utilizes T-cell-depleted, Mismatched Donor Bone Marrow Transplants in Conjunction with Veto T-cell Transplants to Correct Sickle Cell Disease with Minimal Risk as Reported in Bone Marrow Transplantation (BMT) Journal
- « Previous Page
- 1
- …
- 169
- 170
- 171
- 172
- 173
- …
- 336
- Next Page »